Literature DB >> 14512891

MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation.

Marta Burrel1, Josep M Llovet, Carmen Ayuso, Carmela Iglesias, Margarita Sala, Rosa Miquel, Teresa Caralt, Juan Ramon Ayuso, Manel Solé, Marcelo Sanchez, Concepció Brú, Jordi Bruix.   

Abstract

Helical computerized tomography (CT) and magnetic resonance imaging (MRI) are used for staging of hepatocellular carcinoma (HCC) prior to curative treatments but underestimate tumor extension in 30% to 50% of cases when compared with pathologic explants. This study compares a new technology, MRI angiography (MRA), with triphasic helical CT in detection of HCC. Fifty cirrhotic patients, 29 with HCC, undergoing liver transplantation were analyzed. MRA was performed with a 3-D breath-hold fast spoiled gradient-echo sequence by using an effective section thickness of 2 to 2.5 mm. The gold standard was the pathologic examination (liver cut into 5-mm slices). One hundred twenty-seven lesions were identified at the explant: 76 HCC, 13 high-grade dysplastic nodules, 31 macroregenerative nodules, 7 hemangiomas. Diameter of the main HCC nodules was 29 +/- 14 mm and 11 +/- 7 mm for the 47 additional nodules. On a per nodule basis, sensitivity of MRA was superior to CT (58/76 [76%] vs. 43/70 [61%], respectively, P =.001). Sensitivity of MRA for detection of additional nodules decreased with size (>20 mm: 6/6 [100%]; 10-20 mm: 16/19 [84%]; <10 mm: 7/22 [32%]) and was superior to CT for nodules 10 to 20 mm (84% vs. 47%, P =.016). Nonspecific hypervascular nodules >5 mm at MRA were HCC in two thirds of the cases. In conclusion, MRA has a high diagnostic accuracy for HCC > or =10 mm and is more sensitive than triphasic helical CT in nodules sized 10 to 20 mm. MRA is the optimal technique for HCC staging prior to curative therapies.

Entities:  

Mesh:

Year:  2003        PMID: 14512891     DOI: 10.1053/jhep.2003.50409

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  103 in total

1.  Evaluating the validity of model for end-stage liver disease exception points for hepatocellular carcinoma patients with multiple nodules <2 cm.

Authors:  Mariya L Samoylova; Jennifer L Dodge; Neil Mehta; Francis Y Yao; John P Roberts
Journal:  Clin Transplant       Date:  2014-12-01       Impact factor: 2.863

2.  Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinoma.

Authors:  M Sherman; K Burak; J Maroun; P Metrakos; J J Knox; R P Myers; M Guindi; G Porter; J R Kachura; P Rasuli; S Gill; P Ghali; P Chaudhury; J Siddiqui; D Valenti; A Weiss; R Wong
Journal:  Curr Oncol       Date:  2011-10       Impact factor: 3.677

3.  Diagnostic sensitivity of imaging modalities for hepatocellular carcinoma smaller than 2 cm.

Authors:  Keiji Mita; Soo Ryang Kim; Masatoshi Kudo; Susumu Imoto; Taisuke Nakajima; Kenji Ando; Katsumi Fukuda; Toshiyuki Matsuoka; Yoko Maekawa; Yoshitake Hayashi
Journal:  World J Gastroenterol       Date:  2010-09-07       Impact factor: 5.742

4.  Surveillance and diagnosis of hepatocellular carcinoma in patients with cirrhosis.

Authors:  Lorenzo Andreana; Graziella Isgrò; Maria Pleguezuelo; Giacomo Germani; Andrew K Burroughs
Journal:  World J Hepatol       Date:  2009-10-31

5.  Incidence of Occult Intrahepatic Metastasis in Hepatocellular Carcinoma Treated With Transplantation Corresponds to Early Recurrence Rates After Partial Hepatectomy.

Authors:  David D Aufhauser; Eran Sadot; Douglas R Murken; Kevin Eddinger; Maarouf Hoteit; Peter L Abt; David S Goldberg; Ronald P DeMatteo; Matthew H Levine
Journal:  Ann Surg       Date:  2018-05       Impact factor: 12.969

6.  Promising diagnostic and prognostic value of six genes in human hepatocellular carcinoma.

Authors:  Guanqi Zhang; Zhengchun Kang; Hongliang Mei; Zhiyuan Huang; Hanjun Li
Journal:  Am J Transl Res       Date:  2020-04-15       Impact factor: 4.060

7.  Hepatocellular carcinoma: review of current treatment with a focus on targeted molecular therapies.

Authors:  Sonja K Olsen; Robert S Brown; Abby B Siegel
Journal:  Therap Adv Gastroenterol       Date:  2010-01       Impact factor: 4.409

Review 8.  Endoscopic ultrasound in the evaluation of radiologic abnormalities of the liver and biliary tree.

Authors:  Girish Mishra; Jason D Conway
Journal:  Curr Gastroenterol Rep       Date:  2009-04

Review 9.  MRI of hepatocellular carcinoma: an update of current practices.

Authors:  Hina Arif-Tiwari; Bobby Kalb; Surya Chundru; Puneet Sharma; James Costello; Rainner W Guessner; Diego R Martin
Journal:  Diagn Interv Radiol       Date:  2014 May-Jun       Impact factor: 2.630

10.  Rate of observation and inter-observer agreement for LI-RADS major features at CT and MRI in 184 pathology proven hepatocellular carcinomas.

Authors:  Eric C Ehman; Spencer C Behr; Sarah E Umetsu; Nicholas Fidelman; Ben M Yeh; Linda D Ferrell; Thomas A Hope
Journal:  Abdom Radiol (NY)       Date:  2016-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.